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South Africa is doing ‘some things 
right’ in combatting a runaway TB 
epidemic that may be 10 times greater 
than government estimates, but dismal 
infection control at health care facilities 
and inadequate basic directly observed 
treatment short-course strategy (DOTS) 
need emergency attention.
This was the warning sounded 
by Professor Anton Stoltz, chief 
of the Foundation for Professional 
Development’s (FPD) Infectious 
Diseases Unit and founder of the 
equivalent facility at Pretoria Academic 
Hospital.
Addressing the opening session of the 
country’s first TB conference in Durban 
in July, Stoltz said the impression he 
got from feedback received from FPD 
mentors sent to 37 government facilities 
was that there ‘is virtually no infection 
control’.
 ‘It seems that there’s no proper 
infection control anywhere. It’s a real 
problem. We don’t have places that 
have negative pressure that you can put 
the patient in. It’s blowing all over the 
hospital. We’re sitting on a time bomb. 
If health care workers start getting ill 
from MDR, as some are, what are we 
going to do, given our human resources 
situation?’ he asked.
The FPD allocates one or two doctors 
plus a data capturer and mentor to each 
of the 37 government HIV and/or TB 
clinics and hospitals, so Stoltz, who 
pores over their detailed reports, is not 
grasping his claims out of thin air, so to 
speak.
Scary number crunching
In an interview with Izindaba after the 
TB conference, Stoltz anxiously queried 
the official government TB statistics 
of 7 000 MDR TB sufferers, saying the 
World Health Organization (WHO) TB 
Partnership put this at 10 000.
‘But what worries me far more is this 
global study that shows that 20% of all 
TB going into the labs is now MDR. If 
you do your arithmetic based on 1 in 
every 100 South Africans having TB, 
that’s 90 000 MDR patients, over 10 
times the official estimate!’
Stoltz emphasised that ‘we just don’t 
know the figures, but only certain 
people are being tested for MDR and 
XDR, so we’re missing a huge number 
of these folk walking among us. That’s 
very frightening to me’.
South Africa was spending 
generously on its TB control programme 
with 70% of the budget going to MDR 
and XDR TB. However, only around 
20% of the budget was being dedicated 
to the DOTS, aimed at ensuring 
that people with TB complete their 
treatment, thus reducing the chances of 
developing MDR TB.
It cost around R377 to treat (and cure) 
TB, compared with around R50 000 to 
cure MDR TB, if the patient survives. 
A potent contributor to the high 
costs of treating TB is the difficulty in 
diagnosing it in people infected with 
HIV. ‘We struggle to find TB in people 
with HIV and it’s expensive,’ Stoltz 
said.
South Africa’s TB cure rate stands 
at about 57%. This would have to be 
improved ‘dramatically’ if the country 
wanted to make any meaningful impact 
on the epidemic.
Stoltz identified three priorities: 
increase the basic TB cure rate, rethink 
the DOTS strategy and dramatically 
increase infection control. He said that 
on the government’s own admission 
there are no data on 27% of people who 
go through its TB clinics.  ‘They could 
be dead, cured or defaulting, but they 
could also have MDR TB!’ he warned.  
Monitoring and evaluation needed 
urgent improvement.
‘Get the basics right’
‘If I could send out one message it 
would be prevent, prevent and prevent 
ordinary TB. Then you don’t have to 
spend so much money on MDR/XDR’.
He highlighted a recent probe by 
the Medical Research Council (MRC) 
into the main reasons people defaulted 
on their TB treatment which cited the 
attitude of health care workers. Patients 
were reluctant to return to the clinic 
and face widespread demeaning and/or 
dismissive attitudes.
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Stoltz also recommended staggering 
clinic appointment times and improving 
‘down referrals’ to avoid scores 
or hundreds of people sitting and 
standing around all day in often dark, 
unventilated waiting areas.
‘We have over six million HIV-
positive people – so we initiate 
treatment and within a month the 
person is back, adding to the others 
there for the first time. All our clinics 
just overflow, get clogged.’
 ‘We have limitless resources of wind 
and sunshine in this country, I really 
don’t understand why we’re not using 
them,’ he said.
Another largely underreported 
phenomenon impacting on DOTS and 
DOTS-plus was the large population 
of patients with HIV dementia which 
resulted in them simply not taking their 
pills.
What Government is doing 
right…
Some of the things the government 
was doing right included working with 
all medical schools to put final-year 
students into clinics to mitigate the 
staffing crisis, giving the FPD about 
R15 million over the past 18 months 
to educate TB, STI and ART clinic 
workers and committing to making the 
new rapid test for MDR TB available 
within the next few months. The WHO-
approved test will enable laboratories 
to diagnose MDR TB within a day, and 
not the 2 - 3 months as was the case 
previously.
South Africa’s top researchers, policy 
makers, managers and providers have 
meanwhile released the outcome of a 
round-table discussion last year where 
they grappled with ARV access and the 
health system’s capacity to cope with 
burgeoning demand. 
The report, authored by Helen 
Schneider, Dingie van Rensburg 
and David Coetzee, contains the key 
findings and policy recommendations 
from the meeting which they hope 
will feed into the country’s National 
Strategic Plan. One of the main 
insights was that most of the existing 
programmes are still to a large extent 
doctor and pharmacy dependent.
Participants felt strongly that 
integrating ART with HIV-related 
primary health care services, 
particularly with TB, the prevention 
of mother-to-child transmission and 
maternal and child health services 
within a district health system, remains 
critical.
Stoltz said he understood the 
necessity for streamlining HIV and TB 
treatment on the grounds of efficacy but 
unless a grip was obtained on infection 
control, putting patients suffering from 
both diseases in one room was ‘asking 
for trouble’.
Nine key lessons
In summary, nine key overall lessons 
and recommendations for policy arose 
from evidence presented at last year’s 
think-tank:
1.    Shift the focus of ART 
implementation from ART sites 
to district/sub-district-based 
approaches.
2.    Mobilise and strengthen the existing 
PHC system by reviewing the 
composition, staffing and support 
systems of PHC teams. 
3.    Integrate HIV and TB care, and 
provide both as one service within 
PHC settings. 
4.    Focus on PMTCT, and integrate the 
programme into the treatment of 
children and pregnant women.
5.    Address loss to follow-up by 
introducing services more widely 
spread across the system and by 
strengthening systems for tracing 
dropouts.
6.    Build trust in the public health 
system, by seeing the system 
from the household and patient’s 
perspective so as to better 
understand barriers to use of 
services.
7.    Simplify and standardise approaches 
to implementation for patients, 
programme governors and local 
providers to promote better access 
and enhanced quality.
8.    Strengthen prevention and the 
health system response to other 
diseases and build the PHC and 
district health system.
9.    Improve dialogue among 
researchers, policy makers and 
service providers to promote the 
transfer of lessons, and to harmonise 
and simplify approaches.
The chair of the Durban TB 
conference and former head of TB 
control in the health department, 
Dr Refiloe Matji, said for too long 
stakeholders have been working in silos 
with the impact on the TB epidemic 
fragmented. ‘We need to build one 
team, follow up with one plan, towards 
one goal,’ he said.
Perhaps the mounting crisis will 
galvanise role players into transforming 
think-tanks into battle tanks in a 
consolidated push to gain ascendancy 
over the twin epidemics.
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